Aclarion, Inc. (ACON)
- GlobeNewswire
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform, powered by a
- GlobeNewswire
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs Technology protected by 23 issued US patents, 17 issu
- ACCESSWIRE
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...
